Circulating and synovial antibody profiling of juvenile arthritis patients by nucleic acid programmable protein arrays by Gibson, David S. (Author) et al.
Circulating and synovial antibody profiling of
juvenile arthritis patients by nucleic acid
programmable protein arrays
Gibson et al.
Gibson et al. Arthritis Research & Therapy 2012, 14:R77
http://arthritis-research.com/content/14/2/R77 (17 April 2012)
RESEARCH ARTICLE Open Access
Circulating and synovial antibody profiling of
juvenile arthritis patients by nucleic acid
programmable protein arrays
David S Gibson1,2*†, Ji Qiu3†, Eliseo A Mendoza3, Kristi Barker3, Madeleine E Rooney1 and Joshua LaBaer3
Abstract
Introduction: Juvenile idiopathic arthritis (JIA) is a heterogeneous disease characterized by chronic joint
inflammation of unknown cause in children. JIA is an autoimmune disease and small numbers of autoantibodies
have been reported in JIA patients. The identification of antibody markers could improve the existing clinical
management of patients.
Methods: A pilot study was performed on the application of a high-throughput platform, the nucleic acid
programmable protein array (NAPPA), to assess the levels of antibodies present in the systemic circulation and
synovial joint of a small cohort of juvenile arthritis patients. Plasma and synovial fluid from 10 JIA patients was
screened for antibodies against 768 proteins on NAPPAs.
Results: Quantitative reproducibility of NAPPAs was demonstrated with > 0.95 intra-array and inter-array
correlations. A strong correlation was also observed for the levels of antibodies between plasma and synovial fluid
across the study cohort (r = 0.96). Differences in the levels of 18 antibodies were revealed between sample types
across all patients. Patients were segregated into two clinical subtypes with distinct antibody signatures by
unsupervised hierarchical cluster analysis.
Conclusion: The NAPPAs provide a high-throughput quantitatively reproducible platform to screen for disease-
specific autoantibodies at the proteome level on a microscope slide. The strong correlation between the circulating
antibody levels and those of the inflamed joint represents a novel finding and provides confidence to use plasma
for discovery of autoantibodies in JIA, thus circumventing the challenges associated with joint aspiration. We
expect that autoantibody profiling of JIA patients on NAPPAs could yield antibody markers that can act as criteria
to stratify patients, predict outcomes and understand disease etiology at the molecular level.
Introduction
Juvenile idiopathic arthritis (JIA) is an autoimmune disease
and the second most common disease of childhood after
diabetes, affecting approximately one in every 1,000 chil-
dren [1]. JIA consists of a clinically heterogeneous group
of arthritic disorders that begin before age 16 years and
persist for more than 6 weeks. The cause and pathogenesis
of JIA are still poorly understood. Chronic inflammation
of joints is the only common denominator for all JIA
patients. Of the seven subsets of JIA identified according
to the International League Against Rheumatism classifi-
cation, oligoarticular, extended oligoarticular and polyarti-
cular are the most common [2]. Adverse outcomes can
present to varying degrees regardless of the disease sub-
type [3]. In approximately 25% of children with oligoarti-
cular JIA the disease spreads over time to involve many
joints, a condition known as extended oligoarticular dis-
ease [4]. A number of major challenges exist in the man-
agement of JIA, including a clear and timely diagnosis of
JIA, identification of patients at risk of an aggressive dis-
ease course, and prediction of response to standard treat-
ment. In overcoming these challenges the central aim is to
prevent joint and periarticular damage.
Although clinical manifestations imply the involve-
ment of adaptive immunity in JIA, research into the
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range of autoantigens that drive the humoral response
has significantly lagged behind that of genetic analyses.
Genetic associations between JIA subtypes and HLA or
non-HLA molecules are known to be related to immune
response and associated with other autoimmune diseases
[5,6]. Autoimmune phenomena such as autoreactive T
cells and autoantibodies can be detected readily in most
JIA subgroups [7-9]. In contrast to the majority of circu-
lating proteins, autoantibodies are easy to measure, less
subject to variation in the blood, remarkably stable in
serum samples, and readily detected with well-validated
secondary reagents. Autoantibody tests for anti-cyclic
citrullinated antibody, rheumatoid factor (RF) and anti-
nuclear antigen (ANA) status have been adopted into
clinical practice, and their role in diagnosis is well estab-
lished in adult autoimmune diseases [10].
Autoantibody study in JIA has generally followed in
the wake of research into adult rheumatoid arthritis
(RA) by testing the performance of RA autoantigen tar-
gets in JIA patients. Even though the evidence provided
by this approach has been limited, these studies have
provided a glimpse of the heterogeneous molecular
mechanisms that contribute to the pathogenesis of var-
ious subtypes of JIA. The heterogeneity of JIA is exem-
plified by the fact that findings from RA can only be
applied to a few specific subgroups of JIA patients. RF,
which has a sensitivity of ~80% in RA, is present only in
a small subgroup of patients with polyarticular-onset
JIA [11]. The discovery of RA-specific autoantibodies
against citrullinated proteins prompted tremendous
interest in their performance in JIA patients. Autoanti-
bodies against citrullinated proteins (anti-cyclic citrulli-
nated protein), which are highly specific for RA, can
only be detected in RF-positive JIA patients [12,13], but
are associated with a higher risk of joint erosion, more
aggressive disease and therapeutic resistance [14,15].
Circulating immune complexes containing citrullinated
fibrinogen have been identified in only a small subset of
JIA patients [16]. Antinuclear antibodies, in contrast, are
present in a significant proportion of children with oli-
goarticular, extended oligoarticular and polyarticular dis-
ease, and their presence, to some extent, predicts the
development of uveitis.
Although reliable and sensitive, the ELISA is not prac-
tical as a high-throughput platform for screening large
numbers of autoantibodies. Protein microarrays, on the
other hand, provide a multiplexed, high-throughput
platform to profile thousands of antibodies in parallel.
Despite the potential of harnessing information on the
humoral immune response in JIA, protein microarrays
have only recently been used to investigate JIA [17].
The current study applies an innovative protein array
platform, the nucleic acid programmable protein array
(NAPPA), to provide initial evidence of the true variety
of autoantibodies present in JIA patients. The NAPPA
overcomes some challenges associated with conventional
high-density protein arrays in terms of cost and pro-
grammability, and makes it possible to screen hundreds
of samples for the discovery phase and to design custo-
mized arrays for the validation phase [18,19].
As an exploratory study into the autoantibody comple-
ment of early-stage juvenile arthritis, the goals were to
determine whether NAPPAs are reproducible enough
for autoantibody screening of JIA patients, whether
plasma can be used in place of synovial fluid to reflect
autoantibodies pertinent to joint pathology, and whether
distinct autoantibody expression patterns can be
observed for specific clinical subtypes. Both plasma and
joint (synovial) fluid were therefore analyzed, and results
were compared between duplicate spots within indivi-
dual arrays, within the same sample type across different
patients, and between sample types to highlight poten-
tial correlations and differences in autoantibody levels.
This strategy highlights the performance characteristics
and exhibits the inter-sample and intra-sample compari-
son abilities of the NAPPA platform. Associations with
existing clinical decision-making criteria such as C-reac-
tive protein (CRP) and functional ontology of autoanti-
gens with differentially expressed autoantibodies were
also explored.
Materials and methods
Patient samples
Ten patients with newly diagnosed untreated JIA
according to International League Against Rheumatism
criteria entered this study and were followed for 1 year.
At the time of initial sampling there were six children
with oligoarticular arthritis and four with polyarticular
arthritis (three of whom were RF-negative). At 1 year,
three oligoarticular cases had been reclassified as having
extended oligoarticular JIA. All patients were examined
by a consultant rheumatologist (MER), who confirmed
their diagnosis. For the purposes of this study, only
initial synovial fluids from children with disease duration
< 6 months and untreated disease were studied. Arthro-
centesis and joint steroid injection were performed
according to clinical need.
Clinical details recorded included the subtype of JIA,
age, sex, erythrocyte sedimentation rate (ESR) and CRP.
Local inflammation was defined both as joint swelling
and/or pain and tenderness with a reduced range of
movement on physical examination. All synovial fluids
were aspirated using an aseptic technique; plasma was
obtained at the same visit. Samples were immediately
centrifuged (5,000×g, 15 minutes, 4°C), aliquoted and
stored (at -80°C) for at least 1 year to allow for clinical
reclassification. Medical Ethics Committee approval was
obtained for this study at Green Park Healthcare Trust,
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and patient assent and parent informed consent were
given (Office for Research Ethics Committees Northern
Ireland 408/03).
Nucleic acid programmable protein array production
A total of 768 sequence-verified full-length human genes
in pANT7_cGST or pLDNT7_nFLAG were obtained
from the Center for Personalized Diagnostics at the Ari-
zona State University and are publicly available [20]. The
768 genes were selected to reflect a broad variety of phy-
siological and pathological pathways (Tables S1 and S2 in
Additional File 1). The high-throughput preparation of
high-quality supercoiled DNA for cell-free protein
expression was performed as described [19]. Briefly,
Escherichia-coli-bearing expression plasmids were grown
in 1.5 ml terrific broth for 24 hours with appropriate
antibiotics. Plasmid DNA was purified with the Nucleo-
Prep II anion exchange resin (Macherey-Nagel Inc., Beth-
lehem, PA, USA) using a Biomek FX (Beckman Coulter,
Inc., Fullerton, CA, USA) automated laboratory worksta-
tion. Automated addition of all solutions was accom-
plished using a Matrix WellMate (Thermo Scientific,
Hudson, NH, USA) rapid bulk liquid-dispensing instru-
ment. Purified DNA was precipitated by addition of 0.6
volumes of isopropanol, followed by centrifugation at
5,000 ×g for 30 minutes. The DNA pellet was washed
with 200 μl of 80% ethanol, centrifuged at 5,000 ×g for
15 minutes, dried and resuspended in deuterated water.
Plasmid DNA was supplemented with capture antibody
(50 μg/ml anti-glutathione S-transferase (anti-GST) anti-
body (GE Healthcare Biosciences, Piscataway, NJ, USA) or
anti-FLAG antibody (Sigma-Aldrich, St Louis, MO, USA)),
protein cross-linker (2 mM BS3; Pierce, Rockford, IL,
USA) and BSA (3 mg/ml; Sigma-Aldrich) prior to printing
onto the array surface. All samples were printed using a
Genetix QArray2 with 300 μm solid tungsten pins on ami-
nosilane-coated glass slides. Arrays were stored in an air-
tight container at room temperature until use. The printed
DNA was transcribed and translated in situ using pre-
viously published protocols [19]. The quality of DNA
printing was assessed by PicoGreen staining (Invitrogen,
Carlsbad, CA, USA) and protein expression using anti-
GST mAb (Cell Signaling, Danvers, MA, USA) diluted at
1:200.
Detection of sample antibodies
For autoantibody profiling, printed arrays were after
expression incubated with plasma or synovial fluid diluted
1:600 in the dilution buffer (5% milk with 0.2% Tween
20 in PBS) at 4°C overnight with gentle mixing. Human
antibodies reacting with expressed proteins on array were
detected by Cy5-labeled anti-human IgG (Jackson Immu-
noResearch Laboratories, West Grove, PA, USA). Slides
were scanned with a Tecan powerscanner and the images
were quantified using ArrayPro Image analysis software.
The highly immunogenic Epstein-Barr virus-derived anti-
gen (Epstein-Barr virus nuclear antigen 1) was included as
the positive control antigen. Negative controls included
empty vectors and no DNA controls. Registration spots
for array alignment were printed purified human IgG
proteins.
Differential expression and unsupervised cluster analysis
Ten plasma samples and 10 matched synovial fluid sam-
ples from JIA patients were screened on 768 antigens dis-
played in NAPPA format. The normalized volume for
each spot on each array was calculated by first removing
the background signal estimated by the first quartile of
the nonspots, and then log-transformation of the spot
volumes was used to generate normally distributed data.
The log-normalized volume was used to compare spot
abundance. Differential spot analysis was performed
across the two sample types with Prism 5.03 software
(GraphPad Software Inc., La Jolla, CA, USA). Each com-
parison was filtered to find spots having > 1.45-fold
change in average normalized volume expression
between the sample types.
Expression data were analyzed using Epclust, a generic
data clustering, visualization and analysis tool [21]. Unsu-
pervised hierarchical analysis reordered protein expres-
sion patterns in an agglomerative fashion, using the
unweighted pair-group average with arithmetic mean
clustering procedure. Euclidean ranked correlation was
the similarity measure used to group or separate the
expression data. A heatmap was produced, accompanied
by dual dendrograms depicting the extent of similarity
between different patients and autoantibody levels in the
samples. Information on the functional ontology of target
antigens was mined from the UniProt archive version
2011.03.11 [22].
Serine/threonine kinase-10 antibody ELISA
As the NAPPA is a novel platform and is not routinely
used for clinical measurements, independent verification
of patient antibody levels to a protein randomly selected
from Table 1 was performed by ELISA. GST protein fused
to the full-length serine/threonine kinase-10 gene was
expressed using the rabbit reticulocyte lysates, as above.
Serine/threonine kinase-10-GST protein was applied to an
anti-GST-coated ELISA plate (GE Biosciences, Pittsburgh,
PA, USA) overnight at 4°C. Plates were washed in PBS-
0.05% Tween and blocked with PBS-Tween with 2% milk,
overnight at 4°C. After washing, the plate was incubated
with 1:300 diluted plasma or synovial fluid samples and
the presence of autoantibodies against serine/threonine
kinase-10 was detected by incubation with horseradish
peroxidase-labeled anti-human IgG secondary antibody
(Zymax; Invitrogen). Tetramethyl benzidine substrate
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Table 1 Autoantibodies differentially expressed between circulation and joint
Expression Autoantigen UniProt
accession
Gene
name
Functional ontology biological process
Higher in PL (>
45%)
C-terminal binding protein 1 Q13363 CTBP1 Differentiation, host-virus interaction, transcription regulation
Guanine nucleotide binding
protein (G protein), alpha 13
Q14344 GNA13 Cellular component movement, platelet activation
Presenilin associated, rhomboid-
like protein
Q9H300 PARL -
Trans-2,3-enoyl-CoA reductase Q9NZ01 GPSN2 Fatty acid biosynthesis, lipid synthesis
Cas-Br-M (murine) ecotropic
retroviral transforming sequence
b
Q13191 CBLB Ubiquitin conjugation pathway
Abhydrolase domain containing
16A
O95870 BAT5 -
Tubulin, gamma complex
associated protein 3
Q96CW5 TUBGCP3 Microtubule nucleation at the centrosome
Modulator of apoptosis 1 Q96BY2 MOAP1 Apotosis
Family with sequence similarity
76, member B
Q5HYJ3 FAM76B -
Thyroid hormone receptor,
alpha
P10827 THRA Nuclear hormone receptor, transcriptional regulation
Apolipoprotein A-II P02652 APOA2 Host-virus interaction, lipid transport
Eyes absent homolog 2
(Drosophila)
O00167 EYA2 DNA damage and repair, transcription regulation
IL-6 receptor P08887 IL6R Regulation of the immune response, acute-phase reactions and
hematopoiesis
G protein-coupled receptor 153 Q6NV75 GPR153 -
Histone deacetylase 3 O15379 HDAC3 Anti-apoptosis, histone deacetylation, transcriptional regulation
Actin related protein M1 Q9BYD9 ARPM1 -
Natural killer cell group 7
sequence
Q16617 NKG7 -
Mitogen-activated protein kinase
kinase 7
O14733 MAP2K7 Activation of JUN kinases
Ubiquitin-conjugating enzyme
E2A (RAD6 homolog)
P49459 UBE2A DNA damage and repair, ubiquitin conjugation pathway
v-kit Hardy-Zuckerman 4 feline
sarcoma viral oncogene
homolog
P10721 KIT -
Pleckstrin homology domain
containing, family O member 1
Q53GL0 PLEKHO1 Regulation of the actin cytoskeleton
Adaptor-related protein complex
1, sigma 1 subunit
P61966 AP1S1 Endocytosis, protein transport
neuregulin 1 Q02297 NRG1 Induces growth and differentiation of epithelial, glial, neuronal and
skeletal muscle cells
Peroxisomal biogenesis factor 5 P50542 PEX5 Protein transport
Nuclear receptor subfamily 6,
group A, member 1
Q15406 NR6A1 Transcriptional regulation, cell proliferation
Serine/threonine kinase 10 O94804 STK10 Serine and threonine phosphorylation
Eukaryotic translation initiation
factor 1
P41567 EIF1 Protein biosynthesis through ribosomal complexes
Zinc finger protein 36, C3H
type-like 2
P47974 ZFP36L2 Cell proliferation, regulates response to growth factors
Cartilage oligomeric matrix
protein
P49747 COMP Controls apoptosis and cell adhesion within extracellular matrix
Higher in SF (>
45%)
Actinin, alpha 1 A1L0V1 ACTN1 -
Similar levels in
PL and SF (<
10%)
Protein phosphatase 2, catalytic
subunit, beta isozyme
P62714 PPP2CB Protein dephosphorylation
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(Dako, Carpinteria, CA, USA) was then added and the
reaction stopped with 1 M H2SO4. The 450 nm optical
density signals were read on a SpectralMax plate reader
(Molecular Devices Inc., Sunnyvale, CA, USA). Protein
ELISA analyses were performed in duplicate for each of
the 10 paired patient fluids. Mean absorbance readings
were subjected to paired t test analyses to determine the
significance of any variation in antibody levels between
fluids.
Results
Patients
As measures of the acute-phase reaction, the plasma ESR
and CRP reflect the status of patients when samples were
collected (Table 2). When patients are ranked from those
displaying the lowest levels of inflammation to the highest,
two main groups could be defined: low-medium inflam-
mation (Patients O3, E2, P3, O1, E1 and P1); and med-
ium-high inflammation (Patients O2, P4, E3 and P2). With
particular relevance to the study aim, one-half of the study
patients were positive for routinely measured autoantibo-
dies. RF was detected in only one patient (Patient P2),
whereas ANA antibodies were present in four patients
(Patients O1, O2, E1 and P4).
Intra-slide precision and inter-sample correlation
In total, 768 antigen NAPPAs were probed with
plasma, synovial fluid, and the dilution buffer (to con-
trol for detection antibody specificity) (Figure 1A and
1B). Scatter plots of data that illustrate the correlation
between duplicate protein antigen spots within the
same incubated slide from a single patient for plasma
(Patient O1, r = 0.98) and synovial fluid (Patient O1, r
= 0.98) are shown in Figure 1C. Correlation values of
intra-slide duplicate values for each patient sample
(plasma and synovial fluid, n = 20) were plotted to
illustrate the precision of measurements across the
experiment. An average correlation coefficient of r =
0.98 is observed across all samples (range of r = 0.97 to
0.99) (Figure 1D).
A strong correlation of antibody-antigen spot signals
exists between synovial fluid and plasma samples on a
patient-by-patient basis. A wider range exists in inter-
slide correlations, with an overall trend toward antibody
predominance in plasma. Outliers evident within corre-
lations indicate a select group of antibodies that are
detected at higher levels in one sample type within spe-
cific individuals (that is, Patients O1, O2, P1, P3 and E3;
Figure 2A). The overall mean correlation between fluids
Table 1 Autoantibodies differentially expressed between circulation and joint (Continued)
Peroxisomal biogenesis factor 10 O60683 PEX10 Peroxisome biogenesis
mitogen-activated protein
kinase kinase kinase 7
O43318 MAP3K7 Component of a protein kinase signal transduction cascade; Stimulates
NF-B activation and the p38 mitogen-activated protein kinase pathway
3-Hydroxy-3-methylglutaryl-CoA
synthase 1
Q01581 HMGCS1 Cholesterol, steroin and sterol biosynthesis; lipid synthesis
TNF receptor-associated protein
1
Q12931 TRAP1 Chaperone that expresses an ATPase activity
Troponin C type 1 (slow) P63316 TNNC1 Regulatory protein of striated muscle contraction
Target antigen list of a select group of autoantibodies that were detected either at similar levels or with at least a 45% difference between synovial fluid (SF) and
plasma (PL). The majority of the differentially expressed antibodies are raised in plasma; for example, apolipoprotein AII and cartilage oligomeric matrix protein
(COMP) [Uniprot:P02652, Uniprot:P49747]. Only actinin alpha I targeted antibodies were detected at higher levels in SF within the 45% difference threshold
[Uniprot:A1L0V1]. Six proteins to which mean antibody levels remained static between fluids have also been listed for comparison. The levels of antibodies
against these proteins across individual patient samples are shown in Figure 2A and Figure 3C. STK10, serine/threonine kinase-10.
Table 2 Patient demographics
Patient JIA subgroup (at 1 year) Sex Age at sample (years) WBC (×106 cells/l) ESR (mm/hour) CRP (mg/l) RF ANA titer
O1 Oligoarticular Male 6.6 8.2 10.0 15.0 Negative 1:80
O2 Oligoarticular Female 2.5 12.8 37.0 26.0 Negative 1:80
O3 Oligoarticular Male 8.5 6.6 2.0 6.4 Negative Negative
E1 Extended Oligoarticular Female 7.5 9.5 22.0 9.0 Negative 1:80
E2 Extended Oligoarticular Female 4.7 10.9 10.0 8.4 Negative Negative
E3 Extended Oligoarticular Female 11.0 9.1 62.0 66.5 Negative Negative
P1 Polyarticular Female 3.2 11.0 31.0 4.0 Negative Negative
P2 Polyarticular Female 16.6 11.8 110.0 72.0 231.0 Negative
P3 Polyarticular Female 2.2 7.5 10.0 8.6 Negative Negative
P4 Polyarticular Female 2.6 10.1 45.0 19.1 Negative 1:320
Demographic characteristics and routine laboratory measures of the study subjects. ANA, antinuclear antigen; CRP, C-reactive protein; ESR, erythrocyte
sedimentation rate; JIA, juvenile idiopathic arthritis; RF, rheumatoid factor; WBC, white blood cells.
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across all antibodies detected within all samples is r =
0.96 (range of r = 0.86 to 0.98; Figure 2B).
Differential expression of antibodies between the
circulation and joint
Unsupervised hierarchical cluster analysis of reactivity
data against all 768 screened antigens based on the Eucli-
dean distance measure (unweighted pair-group average
with arithmetic mean) for both plasma and synovial fluid
from all 10 patients revealed distinguishing expression
patterns (Figure 3A). Constructed dendrograms for both
antibody targets and individual patient samples indicate
how the expression levels of proteins that are subject to
similar regulatory pathways cluster and how these may
relate to clinical subgroups within the study cohort.
Tables S3 and S4 in Additional file 1 and Figure S1 in
Additional file 2 list the proteins involved in regulating
two clusters highlighted in Figure 3A. Cluster 1 proteins
are more prevalent in Patients O2, P1, P3 and P4,
whereas cluster 2 is elevated across the whole patient
cohort. A given transcriptional regulator can impact
upon multiple target genes - but it is interesting to note
that even though each cluster contains the same number
of proteins (n = 49), cluster 1 is subject to control by a
smaller number (n = 42) of transcriptional regulators
than those in cluster 2 (n = 95).
Patient samples were clustered into two key groupings:
low antibody levels (Patients O1, O3, E1, E2, E3 and
P3); and high antibody levels (Patients O2, P1, P2 and
P4). It is intriguing that three of the four at-risk patients
Figure 1 Intra-slide duplicate spot correlation. (A1) Nucleic acid programmable protein array (NAPPA) spotted with genes of interest. (A2) All
proteins are tagged at the C-terminus to ensure only full-length translated proteins can be captured in situ by cospotted anti-tag antibodies.
NAPPA has consistent protein amounts displayed at each spot; most are within twofold of the average [18,19]. Proteins are expressed just in
time for assay, which eliminates concern of protein stability. (B) The 768 antigen NAPPAs incubated with plasma (O1PL), synovial fluid (O1SF)
and PBS (to control for detection antibody specificity). Arrays were rinsed and incubated with a fluorophore conjugated anti-human IgG
detection antibody, to probe for antigen-bound antibodies originating from the sample. (C) Scatter plots of data that illustrate the correlation
between duplicate protein antigen spots within the same slide. Correlation of all 768 antigen duplicates from a single patient for plasma (O1PL; r
= 0.983) and synovial fluid (O1SF; r = 0.984) incubated slides. (D) Correlation values of intra-slide duplicate values for each patient sample
(plasma and synovial fluid, n = 20) plotted to illustrate the precision of measurements across the experiment. An average correlation coefficient
of r = 0.981 is observed across all samples (range of r = 0.971 to 0.988). {Figure 1D needed to be redrawn; please find new image for whole
figure}
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previously identified with medium to high levels of CRP
or ESR (Patients O2, P2 and P4) also cluster indepen-
dently with high levels of antibodies relative to the
remaining patients (Figure 3B). The trends observed do
not reach statistical significance by Student’s t test.
Unsupervised hierarchical cluster analysis of autoanti-
body levels detected with differences of at least 45%
between synovial fluid and plasma is shown in Figure
3C. This difference threshold produced a workable list
of 36 antibodies targeting specific antigens (Table 1).
The majority of the differentially expressed antibody
levels are elevated in plasma - that is, apolipoprotein
AII, IL-6 receptor, thyroid hormone receptor alpha and
G-protein coupled receptor 153 [Uniprot:P02652, Uni-
prot:P08887, Uniprot:P10827, Uniprot:Q6NV75]. Only
actinin alpha I targeted antibodies were detected at
higher levels in synovial fluid within the 45% difference
threshold [Uniprot:A1L0V1]. The modest although
significant increase in serine/threonine kinase-10 antibo-
dies was independently confirmed by ELISA (P = 0.038;
Figure 4) [Uniprot:O94804].
Discussion
The production of antibodies against self-antigens (auto-
antibodies) is a characteristic feature of many autoim-
mune diseases. At a clinical level, tests for specific
autoantibodies - such as ANA positivity - are routinely
employed to aid the diagnosis and to track the progress
of these diseases. Traditionally, autoantibodies have
been identified with a one-antigen-at-a-time, hypothesis-
driven approach using methods such as immunofluores-
cence and ELISA.
In contrast, microarrays provide a particularly effective
platform for the systematic study of thousands of pro-
teins in parallel because they are sensitive and require
low sample volumes [23,24]. Protein microarrays involve
Figure 2 Inter-slide correlation between sample types. (A) Scatter plot correlation of antibody-antigen spot signal intensity between plasma
(PL) and synovial fluid (SF) samples on a patient-by-patient basis. Across the study cohort, antibody prevalence in plasma is evident from the
increased signal scale. Antibodies detected at ≤45% higher levels within plasma are indicated by green circular markers; those detected at ≤45%
higher levels within synovial fluid are indicated by yellow triangular markers; a representative set detected at similar mean levels in both sample
types are indicated by black circular markers. This subset of antibody targets is summarized in Table 1. (B) Overall mean correlation between
fluids across all antibodies detected within all samples is r = 0.961 (range of r = 0.859 to 0.981).
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the display of thousands of different proteins with high
spatial density on a microscopic surface. Protein micro-
arrays have been applied to autoimmune biomarker stu-
dies focused on presymptomatic screening and
diagnosis, clinical outcome prognosis and therapeutic
response prediction [25-28]. In the field of autoimmune
disorders, conventional printed arrays have been used to
study RA, systemic lupus erythematosus, multiple
sclerosis, hepatitis and encephalomyelitis [29-34].
The NAPPA is an innovative method to produce pro-
tein microarrays, where cDNAs encoding proteins of
interest are spotted onto activated surfaces and proteins
are produced in situ using mammalian in vitro expres-
sion systems [18,19]. The freshly made protein is cap-
tured by cospotted antibodies specific for a tag encoded
at the end of the amino acid sequence. This approach
circumvents the labor and cost considerations associated
with conventional spotting of labile recombinant pro-
teins into arrays. NAPPA technology recently revealed
that ankylosing spondylitis patients’ autoantibody
responses were targeted towards connective, skeletal and
muscular tissue, unlike those of RA patients [35].
The development of protein microarrays offers a com-
pelling strategy to comprehensively screen antibodies.
When properly executed, these microarrays allow thou-
sands of full-length proteins to be tested simultaneously.
NAPPA technology replaces printing proteins with a
more reliable and less expensive process of printing
DNA, circumventing the need to express, purify and
store proteins. Additionally, this avoids concerns about
Figure 3 Heatmap display of antibody expression pattern. (A) Hiearchical cluster analysis of all 768 screened antibodies ordered by
Euclidean distance measure (unweighted pair-group average with arithmetic mean) for plasma (PL) from all 10 patients, revealing distinguishing
expression patterns. The degree of antibody binding is reflected in the color intensity of the heatmap, whereby the more intense the red, the
more antibody is bound to a given antigen. Clustering and seriation of both antibody target ID’s in rows and individual patient samples in
columns segregates the study cohort by antibody expression levels. Two core patient clusters are revealed: lower antibody levels (Patients O1,
O3, E1, E2, E3 and P3); and higher antibody levels (Patients O2, P1, P2 and P4) (red in patient sample dendrogram). (B) Levels of the
conventional laboratory measures C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are plotted for the study cohort with
patients split into two groups defined above in (A) by low or high antibody levels. Error bars represent standard deviation; no significant
difference exists between the two groups. (C) Hierarchical cluster analysis of autoantibody levels detected with differences of at least 45%
between synovial fluid (SF) and PL. The majority of these antibodies are elevated in plasma relative to synovial fluid.
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protein stability because the proteins are expressed only
at the time of assay. The responses are rapidly identified
because the address of each protein is known in advance
and there are no representation issues; all proteins, even
rare ones, are represented equally (usually in duplicate).
The proteins are arrayed on a single microscope slide
requiring only a few microliters of plasma or serum per
assay. An additional advantage of this approach is that
the data can be evaluated to look for both informative
individual antigens as well as for patterns of antigen
responses with good predictive value [17,36,37]. More-
over, the coupling of clustering algorithms with the
simultaneous comparison of many antigen responses
lends itself well to the determination of antigens with
concordant and independent responses.
In the current study, associations were found between
at-risk patients with elevated CRP or ESR and elevated
antibody levels. The trend is observed in both plasma
and synovial fluid; and although no statistical significance
can be tied to this association, future study with an
expanded cohort could clarify any relationship. Given the
relatively low prevalence of individual autoantibodies,
large numbers of patient and control sera are needed to
demonstrate statistical confidence in new markers. There
is thus a strong need for quantitative reproducibility both
within the array and from array to array so that data can
be analyzed across arrays probed with samples on differ-
ent days to draw statistical conclusions.
The current investigation clearly demonstrated quantita-
tive reproducibility, differential reactivity against different
proteins for individual samples, differential reactivity
among different patients, and the potential to use plasma
samples as a source for multiplex autoantibody discovery
in JIA. The strong correlation between synovial fluid and
plasma antibody levels represents a novel finding and pro-
vides confidence to use plasma for discovery of autoanti-
bodies also found in the pathological joint, thus
circumventing the challenges associated with joint aspira-
tion. Certain antibodies were identified at elevated levels
in plasma (relative to synovial fluid), suggesting that these
may emanate either from immune cells within the circula-
tion or from other tissues around which blood circulates.
Additionally, these elevated antibodies were possibly pro-
duced just prior to sample collection, in response to sti-
mulatory antigens, and have not yet reached homeostatic
levels between the circulation and joint fluids. Intriguingly,
in some cases there is a shift toward a higher signal in
synovial fluid; however, this did not alter the relative abun-
dances of individual species. One possible explanation of
this variation in antibody concentration is the hydration
status of the subjects in question. Overall, however, the
relative abundance of specific antibody species correlates
strongly in most cases.
A wealth of work exists based on conventional tests for
solitary autoantibody species in plasma or serum across a
number of arthritides, including JIA. ANAs are mainly
associated with oligoarticular-onset JIA patients, but are
also present in polyarticular and psoriatic subtypes
[38,39]. Several reports have documented the association
between the presence of ANAs and uveitis in JIA patients
[40]. Distinct autoantigens that contribute to ANA posi-
tivity have not yet been identified. ANA testing is still
performed by indirect immunofluorescence on HEp2
cells [41]. Antibodies against histones, HNRPA2 and
nonhistone chromosomal proteins have been reported in
JIA patients [42]. However, ANAs are present in patients
with other autoimmune diseases as well as healthy indivi-
duals, and might be transiently increased during viral or
bacterial infections. ANA testing to diagnose JIA is there-
fore limited due to its low disease specificity. Several
other autoantigens, such as heat shock glomerular and
endothelial proteins, have also been assessed in JIA, but
the results are inconsistent and of limited value either for
diagnosis or for understanding the disease pathological
mechanism [43-45].
The unsupervised pair-wise clustering of antibody
levels and clinical subtype, albeit in a small cohort,
Figure 4 ELISA verification of serine/threonine kinase-10
antibody levels. The plasma concentrations of anti-serine/
threonine kinase-10 antibodies were confirmed to be significantly
higher in plasma (PL) than in synovial fluid (SL) by ELISA (paired t
test P = 0.038). The paired PL (circular marker) and SF (square
marker) samples from individual juvenile idiopathic arthritis patients
are identified by a dashed line between points. The mean ELISA
reading at 450 nm across the study cohort for each sample type is
represented by a horizontal solid line.
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produced some interesting observations. The expression
levels of antibodies directed at a select group of antigens
appear to segregate patients into two clinically relevant
clusters. The two defined patient groups are distin-
guished by the severity of disease, whereby a higher
antibody titer is associated with an increase of the
acute-phase indicators ESR and CRP. Additionally, a
number of these high-antibody-titer patients tested
ANA-positive or RF-positive, suggesting a trend -
although this would require confirmation in a much lar-
ger patient cohort. Similarly, a recent protein array
study demonstrated that juvenile arthritis patients can
be stratified into distinct molecular subtypes based on
the expression of antibody signatures [17]. Stoll and col-
leagues demonstrated that autoantibodies directed at the
extracellular matrix and nuclear antigens are elevated in
a subgroup of oligoarticular JIA patients that were less
likely to attain clinical remission. Likewise, clinical sub-
typing of adult RA patients by arrays of 10 preselected
antigens has been successfully demonstrated on an
Immunological Multi-Parameter Chip Technology plat-
form produced by Roche Diagnostics Corp., Indianapo-
lis, IN, USA [46]. As a constituent of the observed
elevated signature, antibodies against the IL-6 receptor,
for example, may signal a distortion in the regulation of
the immune and acute phase responses. In fact, syn-
thetic humanized anti-IL-6 receptor embodies one of
the highly selective biologic therapeutic tools now avail-
able to clinicians [47].
Conclusion
In the future we intend to move this work towards a sta-
tistically powered discovery study that will analyze a
much larger cohort with healthy control subjects, to cap-
ture significant biological variance in antibody levels that
correlate with clinically relevant outcomes. Pertinent
clinical questions focused on the management of arthritis
patients that remain unanswered include the prognosis of
adverse outcome (for example, spread of inflammation to
previously unaffected joints) and the timely prediction of
which drugs could abrogate that outcome (for example,
heterogeneity in response amongst JIA subgroups to
expensive biologic drugs). Discovery findings should be
considered a set of leads that then require meticulous
validation, especially with respect to the utility of a multi-
plex antibody signature in a routine clinical setting.
In summary, autoantibody research in JIA has in gen-
eral been hypothesis driven and often adapted from find-
ings of adult RA and other autoimmune diseases.
Unfortunately, even the most established findings in RA
have not proven useful and relevant in all subtypes of
JIA. A comprehensive profiling of the autoantigen reper-
toire in JIA patients will greatly improve our understand-
ing of the molecular and cellular mechanisms that lead to
the loss of immunological tolerance and production of
autoantibodies.
Additional material
Additional file 1: Table S1, a complete list of NAPPA proteins,
presenting the Entrez gene symbol, protein name, cellular location
and molecule type for each protein produced on the NAPPA array
within the current study; Table S2, functional networks of NAPPA
proteins, listing the physiological and pathological functions of 25
networks constructed from the constituents of the NAPPA arrays
used within the current study; Table S3, cluster 1 transcriptional
regulation, listing the proteins responsible for transcriptional
regulation of the target antigens within cluster 1 (Figure 3Aand
Additional File 2 ); and Table S4, cluster 2 transcriptional regulation,
listing the proteins responsible for transcriptional regulation of the
target antigens within cluster 2 (Figure 3Aand Additional File 2).
Additional file 2: Figure S1, transcriptional regulation of antigen
clusters, showing magnified sections of the hierarchical cluster
analysis heatmap in Figure 3Ato illustrate two distinct clusters of 49
proteins targeted by antibodies within the plasma of study
subjects. The proteins responsible for transcriptional regulation of the
target antigens within cluster 1 and cluster 2 are listed in Tables S3 and
Table S4 in Additional File 1, respectively.
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